LISATA THERAP.INC.DL-001 Total Liabilities
LISATA THERAP.INC.DL-001 total liabilities. Based on the latest financial reports, LISATA THERAP.INC.DL-001 (8NE) has total liabilities worth €3.04 Million EUR (≈ $3.55 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check LISATA THERAP.INC.DL-001 liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of LISATA THERAP.INC.DL-001 (2021–2025)
Total liabilities of LISATA THERAP.INC.DL-001 from 2021 to 2025. This chart illustrates how LISATA THERAP.INC.DL-001's total liabilities have evolved over time, based on quarterly financial data.
LISATA THERAP.INC.DL-001 Competitors by Total Liabilities
The table below lists competitors of LISATA THERAP.INC.DL-001 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Quoin Pharmaceuticals Ltd DRC
NASDAQ:QNRX
|
USA | $8.04 Million |
|
Arrow Minerals Ltd
AU:AMD
|
Australia | AU$1.12 Million |
|
Lekoil Limited
F:L5K
|
Germany | €8.36 Million |
|
Voltaic Strategic Resources Ltd
AU:VSR
|
Australia | AU$147.40K |
|
Iconic Minerals Ltd
V:ICM
|
Canada | CA$683.50K |
|
Gladiator Resources Ltd
AU:GLA
|
Australia | AU$168.75K |
|
Neuroone Medical Technologies Corp
NASDAQ:NMTC
|
USA | $2.49 Million |
|
Golden Matrix Group Inc
NASDAQ:GMGI
|
USA | $61.44 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down LISATA THERAP.INC.DL-001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see LISATA THERAP.INC.DL-001 (8NE) total assets.
Liquidity & Leverage Metrics
LISATA THERAP.INC.DL-001 Total Liabilities Ratios Explained
LISATA THERAP.INC.DL-001 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LISATA THERAP.INC.DL-001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LISATA THERAP.INC.DL-001 (2021–2025)
The table below shows the annual total liabilities of LISATA THERAP.INC.DL-001 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €3.14 Million ≈ $3.67 Million |
-44.71% |
| 2024-12-31 | €5.68 Million ≈ $6.65 Million |
-16.40% |
| 2023-12-31 | €6.80 Million ≈ $7.95 Million |
+1.34% |
| 2022-12-31 | €6.71 Million ≈ $7.84 Million |
+33.99% |
| 2021-12-31 | €5.01 Million ≈ $5.85 Million |
-- |
About LISATA THERAP.INC.DL-001
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more